Statement: All the primary trial participants receive the same dose of Letrozole, only certain patients in the secondary trial are administered Exemestane.
Primary_evidence: INTERVENTION 1:    Letrozole   Letrozole 2.5 mg/day for 3 years INTERVENTION 2:    Letrozole + Zoledronic Acid   Letrozole 2.5mg/day for 3 years plus Zoledronic acid 4mg every 6 months
Secondary_evidence: INTERVENTION 1:    Tamoxifen   Tamoxifen 20mg orally daily for 5 years INTERVENTION 2:    Ovarian Function Suppression   Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)   Note: Data were collected separately for the T+OFS and E+OFS participants in the parent study, IBCSG 24-02 (SOFT). The sample size for this Co-SOFT substudy was small, so the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS.